1 2 3 4 5 6	NIALL E. LYNCH (CSBN 157959) LIDIA SPIROFF (CSBN 222253) SIDNEY A. MAJALYA (CSBN 205047) LARA M. KROOP (CSBN 239512) Antitrust Division U.S. Department of Justice 450 Golden Gate Avenue Box 36046, Room 10-0101 San Francisco, CA 94102 Telephone: (415) 436-6660		Filed 5/4/2006
7	Attorneys for the United States		
8	UNITED STATES DIS	STRIC	ΓCOURT
9	NORTHERN DISTRICT OF CALIFORNIA		
10	SAN FRANCISCO DIVISION		
11	UNITED STATES OF AMERICA)	Case No. CR 06-0160 MMC
12 13	v.)))	UNITED STATES AND AKZO NOBEL'S JOINT SENTENCING MEMORANDUM
14	AKZO NOBEL CHEMICALS INTERNATIONAL)	
15 16	B.V. Defendant.)) _)	DATE: May 17, 2006 TIME: 2:30 p.m. COURT: Hon. Maxine M. Chesney
17	JOINT SENTENCING MEMORANDUM		
18	The United States of America and the defendant, Akzo Nobel Chemicals International		
19	B.V. ("Akzo Nobel"), file this Joint Sentencing Memorandum in support of their recommendation		
20	that the Court sentence the defendant to pay a criminal fine of \$32 million. The parties also		
21	request that sentence be imposed on May 17, 2006, based on the current record, without need of		
22	an evidentiary sentencing hearing or a presentence report.		
23	INTRODUC	CTION	[
24	On March 14, 2006, the United States filed a	one-co	ount Information charging Akzo Nobel
25	with participating in a conspiracy in the United States and elsewhere to suppress and eliminate		
26	competition by fixing the prices of hydrogen peroxide beginning on or about July 1, 1998 and		
27	continuing until on or about December 1, 2001, in v	iolatio	n of the Sherman Antitrust Act, 15
28	U.S.C. § 1. Akzo Nobel is scheduled to be arraigne	d on M	ay 17, 2006. Akzo Nobel will waive

JOINT SENTENCING MEMORANDUM-AKZO

2 2

1 indictment and plead guilty under Fed. R. Crim. P. 11(c)(1)(C).

The United States and Akzo Nobel jointly submit this Joint Sentencing Memorandum to request that the Court sentence Akzo Nobel on an expedited basis pursuant to Crim. L.R. 32-1(b). This Memorandum also outlines the material terms of the Plea Agreement between the United States and Akzo Nobel, in the event the Court grants the parties' request to impose a sentence immediately on May 17, 2006, after accepting Akzo Nobel's guilty plea. In conjunction with this Joint Sentencing Memorandum, the United States and Akzo Nobel have filed a Stipulation in Support of Expedited Sentencing and a Proposed Order for Expedited Sentencing Pursuant to L.R. 32-1(b).

The United States and Akzo Nobel respectfully submit that this Memorandum and the
Plea Agreement provide sufficient information for the Court to impose sentence immediately
without a presentence report. In addition, an expedited sentencing would accommodate Akzo
Nobel's corporate representative. If the Court finds that the Plea Agreement and this
Memorandum do not provide sufficient information to allow for the imposition of sentence on the
scheduled date of the plea hearing, the parties are prepared to submit additional information
requested by the Court. A copy of the Akzo Nobel 11(c)(1)(C) Plea Agreement is attached as
Exhibit A to this Memorandum.

MATERIAL TERMS OF AKZO NOBEL PLEA AGREEMENT

The material terms of the Akzo Nobel Plea Agreement include:

1. Akzo Nobel will waive indictment, waive all rights as enumerated in the Plea Agreement, and plead guilty under Fed. R. Crim. P. 11(c)(1) to an Information charging it with participating in a conspiracy in the United States and elsewhere to suppress and eliminate competition by fixing the prices of hydrogen peroxide beginning on or about July 1, 1998 and continuing until on or about December 1, 2001, (the "relevant period") in violation of the Sherman Antitrust Act, 15 U.S.C. § 1. During the relevant period, the defendant was a corporation organized and existing under the laws of the Netherlands, and had its principal place of business in Amersfoort, the Netherlands. During the relevant period, the defendant was a producer of hydrogen peroxide, was engaged in the sale of hydrogen peroxide in the United States

JOINT SENTENCING MEMORANDUM–AKZO 2

and elsewhere, and employed 5,000 or more individuals. The defendant's sales of hydrogen 1 2 peroxide to U.S. customers affected by the conspiracy totaled approximately \$82,900,000.

3 2. The United States and Akzo Nobel agree that the appropriate sentence in this case 4 is a criminal fine of \$32 million and a special assessment of \$400. The fine is to be paid in full 5 within 15 days of the imposition of sentence. Both parties recommend that no term of probation be imposed. Akzo Nobel agrees to have its sentence determined under the United States 6 7 Sentencing Guidelines ("U.S.S.G.," "Sentencing Guidelines," or "Guidelines"), although Akzo 8 Nobel understands the Guidelines are advisory, not mandatory. The United States contends that 9 had this case gone to trial, the United States would have presented evidence to prove that the gain 10 derived from or the loss resulting from the charged offense is sufficient to justify a fine of \$32 11 million, pursuant to 18 U.S.C. § 3571(d). For purposes of this plea and sentencing only, the 12 defendant waives its right to contest this calculation.

3. 13 The United States will not seek restitution in this case in light of the civil class 14 action cases filed against Akzo Nobel, including In re Hydrogen Peroxide Antitrust Litigation, 15 No. 05-666, MDL No. 1682, in the United States District Court, Eastern District of Pennsylvania, 16 which potentially provide for recovery of a multiple of actual damages.

17 4. The United States agrees that it will not bring further criminal charges against 18 Akzo Nobel and its current or former officers, directors, and employees (except for Dag Strömqvist and Börje Andersson, who have been specifically excluded from the Plea Agreement) for their participation in the hydrogen peroxide conspiracy. In return, Akzo Nobel agrees to cooperate fully in the ongoing hydrogen peroxide investigation. Akzo Nobel has already produced documents and other valuable information. Moreover, Akzo Nobel has agreed to make employees available to the United States for interviews and to produce documents located outside the country, which are beyond the jurisdictional reach of the government's grand jury subpoenas. The documents produced, as well as additional proffered cooperation, have substantially assisted the United States in furthering its investigation.

3

111

1	UNITED STATES SENTENCING GUIDELINES CALCULATIONS			
2	The parties agree to the following Sentencing Guidelines calculations, which are based on			delines calculations, which are based on
3	the affected	l hydroge	en peroxide sales in the United States	of \$82.9 million:
4 5	(Volume of Affected Commerce)		\$16.58 million	
6				
7		i.	Base (§ 8C2.5(a))	5
8		ii.	Involvement in or Tolerance of Criminal Activity (§ 8C2.5(b)(1))	5
9		iii.	Prior History (§ 8C2.5(c))	2
10		iv.	Violation of Order (§ 8C2.5(d))	0
11		v.	Obstruction of Justice (§ 8C2.5(e))	0
12 13		vi.	Effective Program to Prevent and Detect Violations of Law (§ 8C2.5(f))	0
14 15		vii.	Self-Reporting, Cooperation, and Acceptance of Responsibility (§ 8C2.5(g)(2))	-2
16	c. Tot	al Culpat	bility Score:	10
17 18		nimum an 3C2.6)	d Maximum Multipliers	2.0 - 4.0
19 20		nimum an 8C2.7)	d Maximum Fine Range	\$33.16 - \$66.32 million
	The United States will move, pursuant to § 8C4.1 of the Sentencing Guidelines, for		of the Sentencing Guidelines, for a	
21	 downward departure from the minimum Guidelines fine to a fine of \$32 million due to Akzo Nobel's substantial assistance in the United States' hydrogen peroxide investigation. Additionally, Akzo Nobel has agreed to produce relevant documents from the United States and abroad as a condition to the government entering into the Plea Agreement. Defendant has agreed to continue to assist in the government's investigation. 			o a fine of \$32 million due to Akzo
22				
23 24				documents from the United States and
24 25				
26 27	///			
27	///			
28	JOINT SENTENCING MEMORANDUM–AKZO 4			

1	DATED: May 3, 2006	Respectfully submitted,
2	AKZO NOBEL CHEMICALS INTERNATIONAL B.V.	U.S. DEPARTMENT OF JUSTICE
3	INTERNATIONAL D.V.	
4	BY: /s/ A. Jan A.J. Eijsbouts	BY:/s/ Niall E. Lynch
5	General Counsel Akzo Nobel Group	Assistant Chief, San Francisco Office Lidia Spiroff
6	COUNSEL FOR DEFENDANT	Sidney A. Majalya Lara M. Kroop
7		Trial Attorneys U.S. Department of Justice Antitrust Division
8	BY:/s/ Gary R. Spratling, Esq. Daniel G. Swanson, Esq.	Antitrust Division 450 Golden Gate Avenue
9	Stephen C. McKenna, Esq. Gibson Dunn & Crutcher LLP	Box 36046, Room 10-0101 San Francisco, CA 94102
10	One Montgomery Street San Francisco, CA 94104	Telephone: (415) 436-6660 Fax: (415) 436-6687
11	Telephone: (415) 393-8200	1 ax. (+15) +50-0007
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
	JOINT SENTENCING MEMORANDUM-AKZO	5

1	NIALL E. LYNCH (CSBN 157959)		
2	LIDIA SPIROFF (CSBN 222253) SIDNEY A. MAJALYA (CSBN 205047) LARA M. KROOP (CSBN 239512) Filed 5/4/2006		
3	Antitrust Division U.S. Department of Justice		
4	450 Golden Gate Avenue Exhibit "A" Box 36046, Room 10-0101		
5	San Francisco, CA 94102 Telephone: (415) 436-6660		
6	Attorneys for the United States		
7			
8	UNITED STATES DISTRICT COURT		
9	NORTHERN DISTRICT OF CALIFORNIA		
10	SAN FRANCISCO DIVISION		
11	UNITED STATES OF AMERICA) No. CR 06-0160 MMC		
12	v.) PLEA AGREEMENT		
13)		
14	AKZO NOBEL CHEMICALS INTERNATIONAL) B.V.,)		
15) Defendant.		
16			
17	PLEA AGREEMENT		
18	The United States of America and AKZO NOBEL CHEMICALS INTERNATIONAL		
19 20	B.V. ("defendant"), a corporation organized and existing under the laws of the Netherlands,		
20 21	hereby enter into the following Plea Agreement pursuant to Rule $11(c)(1)(C)$ of the Federal		
21 22	Rules of Criminal Procedure ("Fed. R. Crim. P."):		
22	RIGHTS OF DEFENDANT 1. The defendant understands its rights:		
23 24	(a) to be represented by an attorney;		
24 25	(a) to be represented by an attorney,(b) to be charged by indictment;		
23 26	(c) as a corporation organized and existing under the laws of the Netherlands,		
20 27	to decline to accept service of the Summons in this case, and to contest the jurisdiction of		
27	the United States to prosecute this case against it in the United States District Court for		
20			
	PLEA AGREEMENT–AKZO NOBEL		
ļ			

1 the Northern District of California; 2 (d) to plead not guilty to any criminal charge brought against it; 3 to have a trial by jury, at which it would be presumed not guilty of the (e) 4 charge and the United States would have to prove every essential element of the charged 5 offense beyond a reasonable doubt for it to be found guilty; 6 (f) to confront and cross-examine witnesses against it and to subpoena 7 witnesses in its defense at trial; 8 to appeal its conviction if it is found guilty; and (g) 9 (h) to appeal the imposition of sentence against it. 10 REEMENT TO PLEAD GUILTY 11 AND WAIVE CERTAIN RIGHTS The defendant knowingly and voluntarily waives the rights set out in Paragraph 12 2. 13 1(b)-(g) above, including all jurisdictional defenses to the prosecution of this case, and agrees 14 voluntarily to consent to the jurisdiction of the United States to prosecute this case against it in 15 the United States District Court for the Northern District of California. The defendant also 16 knowingly and voluntarily waives the right to file any appeal, any collateral attack, or any other 17 writ or motion, including but not limited to an appeal under 18 U.S.C. § 3742, that challenges the 18 sentence imposed by the Court if that sentence is consistent with or below the recommended 19 sentence in Paragraph 8 of this Plea Agreement, regardless of how the sentence is determined by 20 the Court. This agreement does not affect the rights or obligations of the United States as set 21 forth in 18 U.S.C. § 3742(b) and (c). Pursuant to Fed. R. Crim. P. 7(b), the defendant will waive 22 indictment and plead guilty at arraignment to a one-count Information to be filed in the United 23 States District Court for the Northern District of California. The Information will charge the 24 defendant with participating in a conspiracy to suppress and eliminate competition by fixing the 25 price of hydrogen peroxide sold in the United States and elsewhere, beginning on or about July 26 1, 1998 and continuing until on or about December 1, 2001, in violation of the Sherman Antitrust 27 Act, 15 U.S.C. § 1. 28 The defendant, pursuant to the terms of this Plea Agreement, will plead guilty to 3.

1	the criminal charge described in Paragraph 2 above and will make a factual admission of guilt to		
2	the Court in accordance with Fed. R. Crim. P. 11, as set forth in Paragraph 4 below.		
3	FACTUAL BASIS FOR OFFENSE CHARGED		
4	4. Had this case gone to trial, the United States would have presented evidence		
5	sufficient to prove the following facts:		
6	(a) For purposes of this Plea Agreement, the "relevant period" is that period		
7	beginning on or about July 1, 1998 and continuing until on or about December 1, 2001.		
8	During the relevant period, the defendant was a corporation organized and existing under		
9	the laws of the Netherlands. The defendant has its principal place of business in		
10	Amersfoort, the Netherlands. During the relevant period, the defendant, including its		
11	subsidiaries, was a producer of hydrogen peroxide, was engaged in the sale of hydrogen		
12	peroxide in the United States and elsewhere, and employed 5,000 or more individuals.		
13	Hydrogen peroxide is a chemical compound with strong oxidizing properties that is		
14	widely used as a bleaching agent. Hydrogen peroxide has multiple industrial uses,		
15	including applications in the electronics, energy production, mining, cosmetics, food		
16	processing, textiles, and pulp and paper manufacturing industries. During the relevant		
17	period, the defendant's sales of hydrogen peroxide to U.S. customers totaled		
18	approximately \$82,900,000.		
19	(b) During the relevant period, the defendant, through certain executives and		
20	employees, participated in a conspiracy among major hydrogen peroxide producers, the		
21	primary purpose of which was to suppress and eliminate competition by fixing the price		
22	of hydrogen peroxide sold in the United States and elsewhere. In furtherance of the		
23	conspiracy, the defendant, through certain executives and employees, engaged in		
24	discussions with representatives of other major hydrogen peroxide producers. During		
25	these discussions, agreements were reached to fix the price of hydrogen peroxide to be		
26	sold in the United States and elsewhere.		
27	(c) During the relevant period, hydrogen peroxide sold by one or more of the		
28	conspirator firms, and equipment and supplies necessary to the production and		
	2		

1	distribution of hydrogen peroxide, as well as payments for hydrogen peroxide, traveled in		
2	interstate and foreign commerce. The business activities of the defendant and its		
3	co-conspirators in connection with the production and sale of hydrogen peroxide affected		
4	by this conspiracy were within the flow of, and substantially affected, interstate and		
5	foreign trade and commerce.		
6	(d) Hydrogen peroxide affected by this conspiracy was sold by one or more of		
7	the conspirators to customers in this District.		
8	POSSIBLE MAXIMUM SENTENCE		
9	5. The defendant understands that the statutory maximum penalty which may be		
10	imposed against it upon conviction for a violation of Section One of the Sherman Antitrust Act is		
11	a fine in an amount equal to the greatest of:		
12	(a) \$10 million (15 U.S.C. § 1);		
13	(b) twice the gross pecuniary gain the conspirators derived from the crime (18		
14	U.S.C. § 3571(c) and (d)); or		
15	(c) twice the gross pecuniary loss caused to the victims of the crime by the		
16	conspirators (18 U.S.C. § 3571(c) and (d)).		
17	6. In addition, the defendant understands that:		
18	(a) pursuant to 18 U.S.C. \S 3561(c)(1), the Court may impose a term of		
19	probation of at least one year, but not more than five years;		
20	(b) pursuant to § 8B1.1 of the United States Sentencing Guidelines		
21	("U.S.S.G.," "Sentencing Guidelines," or "Guidelines"), 18 U.S.C. § 3563(b)(2) or		
22	3663(a)(3), the Court may order it to pay restitution to the victims of the offense; and		
23	(c) pursuant to 18 U.S.C. § 3013(a)(2)(B), the Court is required to order the		
24	defendant to pay a \$400 special assessment upon conviction for the charged crime.		
25	SENTENCING GUIDELINES		
26	7. The defendant understands that the Sentencing Guidelines are advisory, not		
27	mandatory, but that the Court must consider the Guidelines in effect on the day of sentencing,		
28	along with the other factors set forth in 18 U.S.C. §3553(a), in determining and imposing		
	PLEA AGREEMENT-AKZO NOBEL 4		

1 sentence. The defendant understands that the Guidelines determinations will be made by the 2 Court by a preponderance of the evidence standard. The defendant understands that although the 3 Court is not ultimately bound to impose a sentence within the applicable Guidelines range, its 4 sentence must be reasonable based upon consideration of all relevant sentencing factors set forth 5 in 18 U.S.C. § 3553(a). Pursuant to U.S.S.G. § 1B1.8, the United States agrees that 6 self-incriminating information that the defendant provides to the United States pursuant to this 7 Plea Agreement will not be used to increase the volume of affected commerce attributable to the 8 defendant or in determining the defendant's applicable Guidelines range, except to the extent 9 provided in U.S.S.G. § 1B1.8(b).

10

28

SENTENCING AGREEMENT

11 8. Pursuant to Fed. R. Crim. P. 11(c)(1)(C), the United States and the defendant 12 agree that the appropriate disposition of this case is, and agree to recommend jointly that the 13 Court impose, a sentence requiring the defendant to pay to the United States a criminal fine of 14 \$32 million, pursuant to 18 U.S.C. § 3571(d), payable in full before the fifteenth (15th) day after 15 the date of judgment ("the recommended sentence"). The parties agree that there exists no 16 aggravating or mitigating circumstance of a kind, or to a degree, not adequately taken into 17 consideration by the U.S. Sentencing Commission in formulating the Sentencing Guidelines 18 justifying a departure pursuant to U.S.S.G. § 5K2.0. The parties agree not to seek or support any 19 sentence outside of the Guidelines range nor any Guidelines adjustment for any reason that is not 20 set forth in this Plea Agreement. The parties further agree that the recommended sentence set 21 forth in this Plea Agreement is reasonable.

22 (a) The defendant understands that the Court will order it to pay a \$400 23 special assessment, pursuant to 18 U.S.C. § 3013(a)(2)(B), in addition to any fine 24 imposed.

25 (b) Both parties will recommend that no term of probation be imposed, but the 26 defendant understands that the Court's denial of this request will not void this Plea 27 Agreement.

(c) The United States and the defendant jointly submit that this Plea 5 PLEA AGREEMENT-AKZO NOBEL

Agreement, together with the record that will be created by the United States and the defendant at the plea and sentencing hearings, and the further disclosure described in Paragraph 10, will provide sufficient information concerning the defendant, the crime charged in this case, and the defendant's role in the crime to enable the meaningful exercise of sentencing authority by the Court under 18 U.S.C. § 3553. The United States and defendant agree to request jointly that the Court accept the defendant's guilty plea and impose sentence on an expedited schedule as early as the date of arraignment, based upon the record provided by the defendant and the United States, under the provisions of Fed. R. Crim. P. 32(c)(1)(A)(ii), U.S.S.G. § 6A1.1, and Rule 32-1(b) of the Criminal Local Rules. The Court's denial of the request to impose sentence on an expedited schedule will not void this Plea Agreement.

(d) The United States contends that had this case gone to trial, the United
States would have presented evidence to prove that the gain derived from or the loss
resulting from the charged offense is sufficient to justify the recommended sentence set
forth in this paragraph, pursuant to 18 U.S.C. § 3571(d). For purposes of this plea and
sentencing only, the defendant waives its rights to contest this calculation.

17 9. The United States and the defendant agree that the applicable Guidelines fine 18 range exceeds the fine contained in the recommended sentence set out in Paragraph 8 above. 19 Subject to the full and continuing cooperation of the defendant, as described in Paragraph 13 of 20 this Plea Agreement, and prior to sentencing in this case, the United States agrees that it will 21 make a motion, pursuant to U.S.S.G. § 8C4.1, for a downward departure from the Guidelines 22 fine range and will request that the Court impose the recommended sentence set out in Paragraph 23 8 of this Plea Agreement because of the defendant's substantial assistance in the government's 24 investigation and prosecution of violations of federal criminal law in the hydrogen peroxide 25 industry and in other chemical industries.

10. Subject to the ongoing, full, and truthful cooperation of the defendant described in
Paragraph 13 of this Plea Agreement, and before sentencing in the case, the United States will
fully advise the Court and the Probation Office as to: (i) the fact, manner, and extent of the

1

2

3

4

5

6

7

8

9

10

defendant's cooperation and its commitment to prospective cooperation with the United States'
 investigation and prosecutions; (ii) all material facts relating to the defendant's involvement in
 the charged offense; and (iii) all other relevant conduct.

4 11. The United States and the defendant understand that the Court retains complete
5 discretion to accept or reject the recommended sentence provided for in Paragraph 8 of this Plea
6 Agreement.

(a) If the Court does not accept the recommended sentence, the United States and the defendant agree that this Plea Agreement, except for Paragraph 11(b) below, shall be rendered void.

10 (b) If the Court does not accept the recommended sentence, the defendant 11 will be free to withdraw its guilty plea (Fed. R. Crim. P. 11(c)(5) and (d)). If the 12 defendant withdraws its plea of guilty, this Plea Agreement, the guilty plea, and any 13 statement made in the course of any proceedings under Fed. R. Crim. P. 11 regarding the 14 guilty plea or this Plea Agreement or made in the course of plea discussions with an 15 attorney for the government shall not be admissible against the defendant in any criminal 16 or civil proceeding, except as otherwise provided in Fed. R. Evid. 410. In addition, the 17 defendant agrees that, if it withdraws its guilty plea pursuant to this subparagraph of the 18 Plea Agreement, the statute of limitations period for any offense referred to in Paragraph 19 15 of this Plea Agreement will be tolled for the period between the date of the signing of 20 the Plea Agreement and the date the defendant withdrew its guilty plea or for a period of 21 sixty (60) days after the date of the signing of the Plea Agreement, whichever period is 22 greater.

12. In light of the civil class action cases filed against the defendant, which potentially
provide for a recovery of a multiple of actual damages, the United States agrees that it will not
seek a restitution order for the offense charged in the Information.

26

7

8

9

DEFENDANT'S COOPERATION

13. The defendant and its parents and subsidiaries that are engaged in the sale or
production of hydrogen peroxide (collectively, "related entities") will cooperate fully and

truthfully with the United States in the prosecution of this case, the conduct of the current federal
 investigation of violations of federal antitrust and related criminal laws involving the
 manufacture or sale of hydrogen peroxide, any other federal investigation resulting therefrom,
 and any litigation or other proceedings arising or resulting from any such investigation to which
 the United States is a party ("federal proceeding"). The ongoing, full, and truthful cooperation
 of the defendant shall include, but not be limited to:

(a) producing to the United States all non-privileged documents, information,
and other materials, wherever located, in the possession, custody, or control of the
defendant or any of its related entities, requested by the United States in connection with
any federal proceeding; and

11 (b) using its best efforts to secure the ongoing, full, and truthful 12 cooperation, as defined in Paragraph 14 of this Plea Agreement, of the current and former 13 directors, officers, and employees of the defendant or any of its related entities as may be 14 requested by the United States, but excluding Dag Strömqvist and Börje Andersson, 15 including making such persons available in the United States and at other mutually 16 agreed-upon locations, at the defendant's expense, for interviews and the provision of 17 testimony in grand jury, trial, and other judicial proceedings in connection with any 18 federal proceeding.

19 14. The ongoing, full, and truthful cooperation of each person described in Paragraph
20 13(b) above will be subject to the procedures and protections of this paragraph, and shall
21 include, but not be limited to:

(a) producing in the United States and at other mutually agreed-upon
 locations all non-privileged documents, including claimed personal documents, and other
 materials, wherever located, requested by attorneys and agents of the United States;

(b) making himself or herself available for interviews in the United States and
at other mutually agreed-upon locations, not at the expense of the United States, upon the
request of attorneys and agents of the United States;

28 (c) responding fully and truthfully to all inquiries of the United States in PLEA AGREEMENT-AKZO NOBEL 8 connection with any federal proceeding, without falsely implicating any person or intentionally withholding any information, subject to the penalties of making false statements (18 U.S.C. § 1001) and obstruction of justice (18 U.S.C. § 1503);

(d) otherwise voluntarily providing the United States with any non-privileged material or information not requested in (a) - (c) of this paragraph that he or she may have that is related to any federal proceeding;

(e) when called upon to do so by the United States in connection with any federal proceeding, testifying in grand jury, trial, and other judicial proceedings fully, truthfully, and under oath, subject to the penalties for perjury (18 U.S.C. § 1621), for making false statements or declarations in grand jury or court proceedings (18 U.S.C. § 1623), for contempt (18 U.S.C. §§ 401-402), and for obstruction of justice (18 U.S.C. § 1503); and

(f) agreeing that, if the agreement not to prosecute him or her in this Plea
 Agreement is rendered void under Paragraph 16(c), the statute of limitations period for
 any relevant offense as defined in Paragraph 16(a) will be tolled as to him or her for the
 period between the date of the signing of this Plea Agreement and six (6) months after
 the date that the United States gave notice of its intent to void its obligations to that
 person under the Plea Agreement.

GOVERNMENT'S AGREEMENT

15. Upon acceptance of the guilty plea called for by this Plea Agreement and the imposition of the recommended sentence, and subject to the cooperation requirements of Paragraph 13 of this Plea Agreement, the United States agrees that it will not bring further criminal charges against the defendant or any of its related entities for any act or offense committed before the date of this Plea Agreement that was undertaken in furtherance of an attempted or completed antitrust conspiracy involving the manufacture or sale of hydrogen peroxide. The nonprosecution terms of this paragraph do not apply to civil matters of any kind, to any violation of the federal tax or securities laws, or to any crime of violence.

16. The United States agrees to the following:

PLEA AGREEMENT-AKZO NOBEL

(a) Upon the Court's acceptance of the guilty plea called for by this Plea
Agreement and the imposition of the recommended sentence and subject to the
exceptions noted in Paragraph 16(c), the United States will not bring criminal charges
against any current or former director, officer, or employee of the defendant or its related
entities for any act or offense committed before the date of this Plea Agreement and
while that person was acting as a director, officer, or employee of the defendant or its
related entities that was undertaken in furtherance of an attempted or completed antitrust
conspiracy involving the manufacture or sale of hydrogen peroxide ("relevant offense"),
except that the protections granted in this paragraph shall not apply to Dag Strömqvist or
Börje Andersson;

(b) Should the United States determine that any current or former director, officer, or employee of the defendant or its related entities may have information relevant to any federal proceeding, the United States may request that person's cooperation under the terms of this Plea Agreement by written request delivered to counsel for the individual (with a copy to the undersigned counsel for the defendant) or, if the individual is not known by the United States to be represented, to the undersigned counsel for the defendant;

(c) If any person requested to provide cooperation under Paragraph 16(b) fails
to comply with his or her obligations under Paragraph 14, then the terms of this Plea
Agreement as they pertain to that person, and the agreement not to prosecute that person
granted in this Plea Agreement, shall be rendered void;

(d) Except as provided in Paragraph 16(e), information provided by a person described in Paragraph 16(b) to the United States under the terms of this Plea Agreement pertaining to any relevant offense, or any information directly or indirectly derived from that information, may not be used against that person in a criminal case, except in a prosecution for perjury (18 U.S.C. § 1621), making a false statement or declaration (18 U.S.C. §§ 1001, 1623), or obstruction of justice (18 U.S.C. § 1503);

(e) If any person who provides information to the United States under this

Plea Agreement fails to comply fully with his or her obligations under Paragraph 14 of this Plea Agreement, the agreement in Paragraph 16(d) not to use that information or any information directly or indirectly derived from it against that person in a criminal case shall be rendered void;

(f) The nonprosecution terms of this paragraph do not apply to civil matters of any kind, to any violation of the federal tax or securities laws, or to any crime of violence; and

8 (g) Documents provided under Paragraphs 13(a) and 14(a) shall be deemed
9 responsive to outstanding grand jury subpoenas issued to the defendant or any of its
10 related entities.

11 17. The United States agrees that when any person travels to the United States for 12 interviews, grand jury appearances, or court appearances pursuant to this Plea Agreement, or for 13 meetings with counsel in preparation therefor, the United States will take no action, based upon 14 any relevant offense, to subject such person to arrest, detention, or service of process, or to 15 prevent such person from departing the United States. This paragraph does not apply to an 16 individual's commission of perjury (18 U.S.C. § 1621), making false statements (18 U.S.C. § 17 1001), making false statements or declarations in grand jury or court proceedings (18 U.S.C. § 1623), obstruction of justice (18 U.S.C. § 1503), or contempt (18 U.S.C. §§ 401-402) in 18 19 connection with any testimony or information provided or requested in any federal proceeding. The defendant understands that it may be subject to administrative action by 20 18. 21 federal or state agencies other than the United States Department of Justice, Antitrust Division, 22 based upon the conviction resulting from this Plea Agreement, and that this Plea Agreement in 23 no way controls whatever action, if any, other agencies may take. However, the United States 24 agrees that, if requested, it will advise the appropriate officials of any governmental agency 25 considering such administrative action of the fact, manner, and extent of the cooperation of the 26 defendant and its related entities as a matter for that agency to consider before determining what 27 administrative action, if any, to take.

28 ///

1

2

3

4

5

6

7

PLEA AGREEMENT-AKZO NOBEL

1	REPRESENTATION BY COUNSEL	
2	19. The defendant has been represented by counsel and is fully satisfied that its	
3	attorneys have provided competent legal representation. The defendant has thoroughly reviewed	
4	this Plea Agreement and acknowledges that counsel has advised it of the nature of the charge,	
5	any possible defenses to the charge, and the nature and range of possible sentences.	
6	VOLUNTARY PLEA	
7	20. The defendant's decision to enter into this Plea Agreement and to tender a plea of	
8	guilty is freely and voluntarily made and is not the result of force, threats, assurances, promises,	
9	or representations other than the representations contained in this Plea Agreement. The United	
10	States has made no promises or representations to the defendant as to whether the Court will	
11	accept or reject the recommendations contained within this Plea Agreement.	
12	VIOLATION OF PLEA AGREEMENT	
13	21. The defendant agrees that, should the United States determine in good faith,	
14	during the period that any federal proceeding is pending, that the defendant or any of its related	
15	entities have failed to provide full and truthful cooperation, as described in Paragraph 13 of this	
16	Plea Agreement, or has otherwise violated any provision of this Plea Agreement, the United	
17	States will notify counsel for the defendant in writing by personal or overnight delivery or	
18	facsimile transmission and may also notify counsel by telephone of its intention to void any of its	
19	obligations under this Plea Agreement (except its obligations under this paragraph), and the	
20	defendant and its related entities shall be subject to prosecution for any federal crime of which	
21	the United States has knowledge including, but not limited to, the substantive offenses relating to	
22	the investigation resulting in this Plea Agreement. The defendant and its related entities may	
23	seek Court review of any determination made by the United States under this Paragraph to void	
24	any of its obligations under the Plea Agreement. The defendant and its related entities agree	
25	that, in the event that the United States is released from its obligations under this Plea Agreement	
26	and brings criminal charges against the defendant or its related entities for any offense referred	
27	to in Paragraph 15 of this Plea Agreement, the statute of limitations period for such offense will	
28	be tolled for the period between the date of the signing of this Plea Agreement and six (6)	
	PLEA AGREEMENT-AKZO NOBEL 12	

l

months after the date the United States gave notice of its intent to void its obligations under this
 Plea Agreement.

22. 3 The defendant understands and agrees that in any further prosecution 4 of it or its related entities resulting from the release of the United States from its obligations 5 under this Plea Agreement, because of the defendant's or its related entities' violation of the Plea 6 Agreement, any documents, statements, information, testimony, or evidence provided by it, its 7 related entities, or current or former directors, officers, or employees of it or its related entities to 8 attorneys or agents of the United States, federal grand juries, or courts, and any leads derived 9 therefrom, may be used against it or its related entities in any such further prosecution. In 10 addition, the defendant unconditionally waives its right to challenge the use of such evidence in 11 any such further prosecution, notwithstanding the protections of Fed. R. Evid. 410. 12 **ENTIRETY OF AGREEMENT** 13 23. This Plea Agreement constitutes the entire agreement between the United States 14 and the defendant concerning the disposition of the criminal charge in this case. This Plea 15 Agreement cannot be modified except in writing, signed by the United States and the defendant. 16 26. The undersigned is authorized to enter this Plea Agreement on behalf of the 17 defendant as evidenced by the Power of Attorney of the defendant attached to, and incorporated 18 by reference in, this Plea Agreement. 19 27. The undersigned attorneys for the United States have been authorized 20 by the Attorney General of the United States to enter this Plea Agreement on behalf of the 21 United States. 22 111 23 111 24 111 25 111 26 /// 27 /// 28 111 PLEA AGREEMENT-AKZO NOBEL 13

1	26. A facsimile signature shall be d	leemed an original signature for the purpose of	
2	executing this Plea Agreement. Multiple signature pages are authorized for the purpose of		
3	executing this Plea Agreement.		
4	DATED: March 14, 2006		
5		Respectfully submitted,	
6			
7			
8	BY:/s/ A. Jan A.J. Eijsbouts	_ BY:/s/	
9	General Counsel	Assistant Chief, San Francisco Office	
10	Akzo Nobel Group	Lidia Spiroff Sidney A. Majalya	
11	COUNSEL FOR DEFENDANT	Lara M. Kroop Trial Attorneys United States Department of Justice	
12	BY:/s/ Gary R. Spratling, Esq.	_ Antitrust Division 450 Golden Gate Avenue	
13	Daniel G. Swanson, Esq. Stephen C. McKenna, Esq.	Box 36046, Room 10-0101 San Francisco, CA 94102	
14	Gibson, Dunn & Crutcher LLP One Montgomery Street	Telephone: (415) 436-6660	
15	Suite 3100 San Francisco, CA 94104		
16	Telephone: (415) 393-820		
17			
18			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28			
	PLEA AGREEMENT–AKZO NOBEL	14	
	l		



POWER OF ATTORNEY

The undersigned, Mr. P.J.F. Gommers and Mr. C.W. van Zuijlen, directors of Akzo Nobel Management B.V., which is the sole director of Akzo Nobel Chemicals International B.V. (the "Company"),

herewith decide,

10.500.500.200

- That Mr. A.J.A.J. Elisbouts, General Counsel of the Akzo Nobel Group, is authorized, empowered and directed to execute and deliver, in the name of and on behalf of the Company, the Plea Agreement between Akzo Nobel Chemicals International B.V. and the United States of America in substantially the form of the draft appended hereto; and further
- That Mr. A.J.A.J. Eijsbouts, General Counsel of the Akzo Nobel Group, Mr. Gary R. Spratling, a partner of the firm of Gibson, Dunn & Crutcher LLP (the "Law Firm"), Mr. Daniel G. Swanson, also a partner of the Law Firm, Mr. Stephen C. McKenna, an associate of the Law Firm, and any other member of the Law Firm may represent the Company at any hearing in order to waive indictment and plead guilty in accordance with the provisions of the above-referenced Plea Agreement; and further
- That Mr. A.J.A.J. Eljsbouts, General Counsel of the Akzo Nobel Group, Mr. Gary R. Spratting, a partner of the Law Firm, Mr. Daniel G. Swanson, also a partner of the Law Firm, Mr. Stephen C. McKenna, an associate of the Law Firm, and any other member of the Law Firm are hereby authorized and empowered on behalf of the Company to walve the preparation of a presentence report and proceed immediately to sentencing, to provide information to the Court in conjunction with sentencing, and to represent the Company at any sentencing hearing; and further
- That Mr. A.J.A.J. Eijsbouts, General Counsel of the Akzo Nobel Group, any of the officers of the Company, Mr. Gary R. Spratling, a partner of the Law Firm, Mr. Daniel G. Swanson, also a partner of the Law Firm, Mr. Stephen C. McKenna, an associate of the Law Firm, and any other member of the Law Firm are hereby authorized and empowered to take any and all actions reasonably required or appropriate in order to carry out the intent and purpose of the preceding resolutions.

AKZO NOBEL CHEMICALS INTERNATIONAL B.V. By: Gommers Director, Akzo Nobel Management B.V. and

By:

C.W. van Zuillen

Director, Akzo Nobel Management B.V.